Abstract
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
May 15, 2025
Jennifer D. Bernt, DNP, FNP-C, AOCNP, Rita Million, PhD, RN, PHNA-BC, CNE, COI, Nicole S. Pham, MPH Et al.
May 15, 2025
Nancy W. Stead, MD, Andria P. Caton, RN, OCN, CHPN
May 15, 2025